Here's What This Label Expansion Could Mean for Eli Lilly Investors

Jardiance, a medication well-known for treatment of type 2 diabetes, now has another importance use. This past month, Eli Lilly (NYSE: LLY) and its German partner Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) had approved it for reducing the risk of hospitalization and death from systolic heart failure.  

This could be good news for both patients and investors. Let's examine the data that led the FDA to reach this decision, what kind of revenue it could translate into for Jardiance, and what it means for Eli Lilly overall.

Image source: Getty Images.

Continue reading

Source Fool.com